Eledon Pharmaceuticals, Inc. (ELDN) financial statements (2022 and earlier)

Company profile

Business Address 19900 MACARTHUR BLVD.
IRVINE, CA 92612
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments84,833114,1958,79112,97217,23323,22324,023
Cash and cash equivalents84,833114,1958,79112,97217,23323,22324,023
Restricted cash and investments    70150 
Receivables 110245    
Prepaid expense1,4401,1987796741,679  
Other current assets34385463018  
Other undisclosed current assets2,03989102  6,17043,147
Total current assets:88,346115,6309,97114,27619,00029,54367,170
Noncurrent Assets
Operating lease, right-of-use asset768138316
Property, plant and equipment  5142598489
Intangible assets, net (including goodwill)48,64848,648 1,8671,867  
Goodwill48,64848,648 1,8671,867  
Restricted cash and investments     120270
Other noncurrent assets400383639869  45
Other undisclosed noncurrent assets32,38632,386     
Total noncurrent assets:82,20281,5559602,7501,892218804
TOTAL ASSETS:170,548197,18510,93117,02620,89229,76167,974
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,4741,6197051,7996872,8196,162
Accounts payable1,8131,3663296894184301,208
Accrued liabilities2501551372081582,3894,954
Employee-related liabilities1,41198239902111  
Debt  180    
Postemployment benefits liability    668  
Other undisclosed current liabilities927864437    
Total current liabilities:4,4012,4831,3221,7991,3552,8196,162
Noncurrent Liabilities
Long-term debt and lease obligation400 144    
Operating lease, liability400 144
Liabilities, other than long-term debt1,7524,106    88
Deferred income tax liabilities1,7524,106 
Other liabilities      88
Other undisclosed noncurrent liabilities     84 
Total noncurrent liabilities:2,1524,106144  8488
Other undisclosed liabilities   73585  
Total liabilities:6,5536,5891,4662,5341,4402,9036,250
Stockholders' equity
Stockholders' equity attributable to parent163,995190,5969,46514,49219,45226,85861,724
Common stock141513972323
Additional paid in capital278,880270,97467,03456,05446,951196,233193,194
Accumulated other comprehensive loss     (1)(55)
Accumulated deficit(114,899)(80,393)(57,582)(41,571)(27,506)(169,397)(131,438)
Total stockholders' equity:163,995190,5969,46514,49219,45226,85861,724
TOTAL LIABILITIES AND EQUITY:170,548197,18510,93117,02620,89229,76167,974

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(36,867)(18,465)(16,051)(14,060)(13,121)(38,123)(45,261)
Operating loss:(36,867)(18,465)(16,051)(14,060)(13,121)(38,123)(45,261)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
77940(5)5  
Other undisclosed loss from continuing operations before equity method investments, income taxes (4,829)     
Loss from continuing operations before income taxes:(36,860)(23,215)(16,011)(14,065)(13,116)(38,123)(45,261)
Income tax benefit2,354404     
Net loss:(34,506)(22,811)(16,011)(14,065)(13,116)(38,123)(45,261)
Other undisclosed net income attributable to parent     164174
Net loss available to common stockholders, diluted:(34,506)(22,811)(16,011)(14,065)(13,116)(37,959)(45,087)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(34,506)(22,811)(16,011)(14,065)(13,116)(38,123)(45,261)
Comprehensive loss:(34,506)(22,811)(16,011)(14,065)(13,116)(38,123)(45,261)
Other undisclosed comprehensive income, net of tax, attributable to parent     218119
Comprehensive loss, net of tax, attributable to parent:(34,506)(22,811)(16,011)(14,065)(13,116)(37,905)(45,142)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: